Treatments
Safe, ANVISA-registered options prescribed by doctors after a complete profile evaluation.
Injectable Semaglutide
Active ingredient found in treatments such as Ozempic® and Wegovy®. Prescription required.
Injectable semaglutide is a GLP-1 receptor agonist administered subcutaneously once weekly. It acts on the brain to regulate satiety and on the stomach to slow digestion, resulting in consistent and significant body weight reduction.
- Weekly application — just once per week
- Most significant weight loss among GLP-1s
- Proven cardiovascular risk reduction
- Sustained appetite control throughout the week
Tirzepatide
Active ingredient found in treatments such as Mounjaro®. Prescription required.
Tirzepatide is a dual GIP and GLP-1 receptor agonist, representing a new generation of treatments. By activating two gut hormones simultaneously, it enhances both appetite control and glucose metabolism, with superior results in clinical studies.
- Dual GIP + GLP-1 mechanism for greater efficacy
- Greatest weight loss observed in clinical studies
- Significant improvement in insulin sensitivity
- Weekly application with pre-filled pen
Liraglutide
Active ingredient found in treatments such as Saxenda® and Olire®. Prescription required.
Liraglutide is a daily GLP-1 receptor agonist. It was one of the first GLP-1 medications approved for obesity. It works by reducing appetite and promoting satiety, being an accessible and well-established option for weight management.
- Well-established treatment with extensive clinical evidence
- Most accessible option among GLP-1 treatments
- Gradual titration for better tolerability
- Widely documented safety profile
Compare treatments
Your doctor will recommend the best treatment for your profile after a complete evaluation.
| Treatment | Route | Frequency | Mechanism | Typical results |
|---|---|---|---|---|
| Injectable Semaglutide | Injectable (subcutaneous) | Weekly | GLP-1 agonist | 10–15% of weight in 6–12 months |
| Tirzepatide | Injectable (subcutaneous) | Weekly | Dual GIP + GLP-1 agonist | 15–22% of weight in 12 months |
| Liraglutide | Injectable (subcutaneous) | Daily | GLP-1 agonist | 5–8% of weight in 6 months |
* Typical results based on published clinical studies. Individual results may vary. Prescription depends on individual medical evaluation.
Safety and side effects
All active ingredients used are registered and approved by ANVISA. Continuous medical follow-up is essential to ensure treatment safety and efficacy.
Most common side effects
- Mild to moderate nausea (most common at treatment start)
- Diarrhea or constipation
- Abdominal pain or gastric discomfort
- Decreased appetite
- Headache
Important:The prescription of any medication depends on individual medical evaluation. Do not start, change, or discontinue any treatment without your doctor's guidance. If you experience adverse effects, contact the medical team immediately.
All trademarks mentioned are property of their respective owners. Medications subject to medical prescription.